


PHARMACEUTICAL 2022

ROYALTY PHARMA

Royalty Pharma plc Rank 209 of 466







PHARMACEUTICAL 2022

Royalty Pharma plc Rank 209 of 466

The relative strengths and weaknesses of Royalty Pharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Royalty Pharma plc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 221% points. The greatest weakness of Royalty Pharma plc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 160% points.

The company's Economic Capital Ratio, given in the ranking table, is 150%, being 72% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	2,878,211
Cost of Goods Sold	0
Intangible Assets	5,670
Liabilities, Current	171,250
Liabilities, Non-Current	7,096,070
Other Assets	14,631,984
Other Compr. Net Income	-643,619
Other Expenses	475,838
Other Liabilities	0
Other Net Income	-189,514
Other Revenues	2,289,463
Property and Equipment	0
Research and Development	200,084
Selling, General and Administrative Expense	182,826

Output Variable	Value in 1000 USD
Assets	17,515,865
Liabilities	7,267,320
Expenses	858,748
Revenues	2,289,463
Stockholders Equity	10,248,545
Net Income	1,241,201
Comprehensive Net Income	919,392
Economic Capital Ratio	150%

